Table 1. Baseline characteristics of the study participants (HIV positive with CD4+ T cell count>350, n = 487).

Parameter	IRF1 619 genotype			p-value
	AA	AC	CC
% Total number (n = 487)	8.9	43.1	48	–
% Female	100	100	100	–
% Kenyan	90	78	69	–
% Tanzanian	10	21	29	–
% Ugandan	–	1	2	–
Age (median, IQR)	42 (34–46.5)	36 (33–43)	38 (33–43)	0.101
Follow-up, days (median, IQR)	2023 (740–3241)	1462 (351.8–3069.3)	1746 (469.5–3261.5)	0.219
CD4 counts at baseline (median, IQR)	508 (407.2–751.5)	590.5 (447.3–794.8)	576 (455–708.5)	0.508
No. of CD4 counts/participant (median, IQR)	9 (3.5–15.5)	7.5 (3.0–13.8)	8 (3.0–14.0)	0.101
Treatment	ART-naïve	ART-naïve	ART-naïve	–
% with VL (n = 263)*	10.6	40	49.4	–
Average log copies/ml (median, IQR)	3.1(1.7–4.0)	3.1(2.0–4.0)	3.0(1.9–4.2)	0.9797

^*Standard of care in Kenya does not include HIV VL; these were analyzed on a random subset of patients (total n = 263).